• No se han encontrado resultados

N-Terminal Pro-Brain Natriuretic Peptide and Risk of Coronary Artery Lesions and Resistance to Intravenous Immunoglobulin in Kawasaki Disease

N/A
N/A
Protected

Academic year: 2018

Share "N-Terminal Pro-Brain Natriuretic Peptide and Risk of Coronary Artery Lesions and Resistance to Intravenous Immunoglobulin in Kawasaki Disease"

Copied!
5
0
0

Texto completo

Loading

Figure

Table I. Demographic, laboratory characteristics of patients at the diagnosis in the group without CAL and with CAL CAL (n = 61) CAL + (n = 19) P value Age (y) 2.0 [0.8-3.3] (2.2  1.6) 1.1 [0.6-2.4](1.8 1.5) .1974 Male sex (%) * 70 58 .4011 Body surface
Table III. Demographic, laboratory characteristics of patients at the diagnosis in the IVIG responsive group, and the IVIG resistant group

Referencias

Documento similar

To explore whether these proteins can bind to their HR2 target, we measured the far-UV CD spectra of mixtures between the proteins and a synthetic peptide encompassing

Government policy varies between nations and this guidance sets out the need for balanced decision-making about ways of working, and the ongoing safety considerations

The main objective of this study was to determine whether the use of TXA in patients undergoing primary or revision TKR with a history of coronary artery disease increased

Effects of resistance training on muscle strength, exercise capacity, and mobility in middle-aged and elderly patients with coronary artery disease: A meta-analysis.

Based on the results of the present study it can be confirmed that Periodontitis is a novel risk factor in Patients with Coronary artery disease or recent Myocardial infarction

In the present study, we analysed the expression of TREM2 and its main sheddase ADAM10 in the brain of sporadic Creutzfeldt-Jakob disease (sCJD) patients and evaluated the role of

The objective of the present study was to determine the DR prevalence, DR risk factors and DR relationship with eGFR in patients with T2DM included in three epidemiological

2 El tratamiento establecido con inmunoglobu- lina intravenosa reduce el riesgo de lesiones corona- rias a menos de 5 %; sin embargo, se han descrito diversas presentaciones